AstraNu Closes $3.5M Seed for Chip-Scale OCT Imaging
Michael Eggleston and Bibek Samanta developed imaging technology at Nokia Bell Labs that now needs a place inside other companies' instruments. Their company, AstraNu, is taking the accumulated work of photonics research into a more specific commercial relationship: supplying an imaging engine that a medical-device manufacturer can design into its own product.
The Murray Hill, New Jersey startup announced a closed $3.5M seed round on November 17, 2026, led by Celesta Capital with co-investment from the New Jersey Innovation Evergreen Fund, an NJEDA program. The money supports its engineering team, partner validation and manufacturing preparation. Ophthalmology is the initial commercial focus, giving the company a defined entry market while it works with developers exploring other applications.
That supplier role makes the financing interesting beyond the amount. AstraNu has to earn a position inside a manufacturer's development program, where the engine's dimensions, imaging performance and integration requirements become part of somebody else's product decisions. The seed round funds work on both sides of that conversation: improving the component and helping potential partners establish how they would use it.
A Bell Labs spin-out develops a supplier business
Nokia's May 2025 launch announcement introduced AstraNu as the first venture in a collaboration with Celesta Capital to commercialize Bell Labs technologies. That launch emphasized ear imaging. The current financing describes an engine supplier beginning commercially in ophthalmology, with ENT among several additional areas of development. The change in emphasis matters to understanding the business being financed now.
The present leadership page identifies Eggleston as Founder and Chief Scientist, Samanta as Founder and VP Engineering, and Kevin Blalock as President and General Manager. Research, engineering and commercialization have visible owners. A prospective device partner can see the people responsible for the underlying technology alongside the executive describing the route toward manufacturing readiness.
For an institutional spin-out, a familiar research origin can help open a door. The assignment inside that door becomes more granular: determining what the component can do in the partner's design, identifying the remaining engineering work and deciding whether the integration is worth carrying forward. Those decisions belong to the manufacturer as well as the supplier. AstraNu's progress will therefore depend on how effectively its team works inside development priorities it does not entirely control.
Smaller optics change the design conversation
AstraNu develops optical coherence tomography, or OCT, imaging technology using integrated photonics. The company traces that platform to Bell Labs' experience with telecom materials, components and optical engineering. In practical business terms, the proposition is to package useful imaging capability into a component that another company can incorporate, rather than requiring AstraNu to own every finished instrument built around it.
The current announcement describes a swept-source engine and reports a module more than 10x smaller than conventional swept-source systems. AstraNu also says its cost is aimed at the price points associated with spectral-domain OCT. These are company-reported comparisons. A manufacturer's evaluation still needs to connect the proposed size and cost advantages to the requirements of a particular device.
Physical space has commercial consequences in that evaluation. A smaller subsystem can give an engineering team more freedom in arranging the rest of an instrument, but the value comes from the design it enables. The component must fit the intended application and perform within that system. That is why partner validation is central to the financing story: the company's claimed advantages become more useful when a manufacturer can evaluate them against a concrete product assignment, with its own constraints and measures of acceptable performance.
State co-investment joins an existing venture relationship
Celesta Capital backed the original spin-out and is leading the seed round. That continuing relationship connects the venture's institutional launch with its next development phase. Celesta Managing Partner and CFO Matthew Marsh describes the scaling assignment in terms of operations and commercial partners, a useful indication of where the investor places the work around the technology.
The NJEDA's October investment announcement separately records approval for up to $1.5M through the New Jersey Innovation Evergreen Fund, matching Celesta. That figure is an approval ceiling, not an additional financing amount to add to the announced $3.5M. The exact state contribution within the closed round was not specified in the funding release.
The state program brings a regional institution into a company built on research associated with Murray Hill. For a reader following commercialization, the useful relationship is the one among the local technical base, a returning venture investor and funding for the people carrying the engine into partner environments. The next stage will require those engineering capabilities even when the prospective customer's product priorities lie elsewhere. The financing gives AstraNu resources to take on that external assignment while developing its internal team.
Partner testbeds bring the product requirements closer
Blalock's description of the financing centers on getting the engine into partner testbeds and preparing manufacturing ahead of customer volume. That sequence gives potential buyers a role in establishing the application case before large-scale delivery. It also helps explain why a seed-stage component company needs commercial relationships while substantial engineering work remains underway.
For medical-device manufacturers, the relevant questions are specific: which design could use the engine, what integration work would fall to each team, and what evidence would support the next development decision? Those are analytical questions raised by AstraNu's supplier model. The announcement leaves customers unnamed and provides no commercial shipment timetable, so the public record offers no basis for treating a finished partner product as already available.
AstraNu's founders now have to carry their knowledge into another engineering organization without losing what makes the platform useful. Eggleston's scientific role, Samanta's engineering responsibility and Blalock's commercial assignment meet at that boundary. As partners evaluate the module, the conversation can move from how much smaller the optics are to what a device team can build around them, and which parts of that work AstraNu must deliver next.
Frequently Asked Questions
Does AstraNu sell a finished medical device?
AstraNu describes itself as a supplier of OCT imaging engines to medical-device, imaging and optics manufacturers. Those partners would incorporate the engine into their own products.
Why is partner validation central to this seed round?
The funding supports evaluation of AstraNu's engine in partner testbeds as well as photonics engineering and manufacturing preparation. That work lets a potential manufacturer assess the engine against the requirements of its own application.
What does the smaller OCT module claim establish?
AstraNu reports that its module is more than 10x smaller than conventional swept-source systems. That is a company-reported comparison, and the funding announcement does not supply independent comparative validation or evidence of clinical outcomes.
How does the state investment relate to the $3.5M round?
The November 17 announcement includes NJIEF co-investment within the $3.5M seed round. NJEDA previously approved up to $1.5M, but the exact amount contributed to the closed round was not disclosed; the approval ceiling should not be added to the round total.
Which applications is AstraNu prioritizing?
The funding announcement identifies ophthalmology as the initial commercial focus. It also describes work with developers in ENT, urology and oncology, without establishing that finished devices for those applications are commercially available.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved